Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Idecabtagene vicleucel - 2seventy bio

Next Previous
Drug Profile

Idecabtagene vicleucel - 2seventy bio

Alternative Names: Abecma; Anti-BCMA CART Cell Therapy - bluebird bio/Celgene; Anti-BCMA CART cells - bluebird bio/Celgene; bb-2121; BMS-986395; ide-cel

Latest Information Update: 10 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator bluebird bio
  • Developer 2seventy bio; bluebird bio; Bristol-Myers Squibb; Celgene Corporation
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Multiple myeloma

Most Recent Events

  • 04 Apr 2024 The approved label for idecabtagene vicleucel cytokine release syndrome, neurologic toxicities, hemophagocytic lymphohistiocytosis/macrophage activation syndrome, prolonged cytopenia, and secondary hematological malignancies carries a black box warning
  • 04 Apr 2024 US FDA approves idecabtagene vicleucel for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy in USA
  • 20 Mar 2024 European Commission approves Idecabtagene vicleucel for Multiple myeloma (Second-line therapy or greater, for patients who have received at least two prior therapies) in European Union, Liechtenstein, Norway and Iceland
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top